Wambeke David J.'s Form 4 filing
DiaMedica Therapeutics Inc. (DMAC) · filed Apr 11, 2023
- Accession no.
- 0001235802-23-000040
- Filed
- Apr 11, 2023
- Trade date
- Apr 10, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $750.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wambeke David J.CIK 0001971798 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2023 | Voting Common Shares, no par value per share | PPurchaseAcquired | +468,750 | $1.60 | +$750,000 | 468,750 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2023 | Common Shares | AGrant or awardAcquired | +140,000 | $0.00 | $0 | 140,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.